Last reviewed · How we verify
Anti-ADHD medication
Anti-ADHD medication is a Small molecule drug developed by NYU Langone Health. It is currently FDA-approved.
The Anti-ADHD medication, marketed by NYU Langone Health, holds a position in the ADHD treatment market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Anti-ADHD medication |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Precision Functional Brain Mapping in Psilocybin (EARLY_PHASE1)
- Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-ADHD medication CI brief — competitive landscape report
- Anti-ADHD medication updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Anti-ADHD medication
What is Anti-ADHD medication?
Who makes Anti-ADHD medication?
What development phase is Anti-ADHD medication in?
Related
- Manufacturer: NYU Langone Health — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing